Sientra Appoints Aesthetic Industry Leader Philippe A. Schaison to Board of Directors
07 Febbraio 2017 - 3:00PM
Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, today
announced the appointment of aesthetics industry veteran executive
Dr. Philippe A. Schaison to the Company’s board of directors,
effective February 6, 2017.
Jeffrey M. Nugent, Chairman and Chief Executive
Officer of Sientra, said, “As one of the premier leaders of the
global aesthetics industry, I have known Philippe for some time and
I am confident that he will bring a unique perspective and will add
to our board’s deep focus on this category. We believe his
experience and insight in building, acquiring, growing, and leading
world class aesthetic products and brands will be instrumental to
the growth of our business. His appointment comes at a critical
juncture for Sientra, as we continue to make progress toward
comprehensive manufacturing supply and on our longer-term objective
of becoming a world class, diversified aesthetics
organization.”
Dr. Schaison has extensive experience leading
global aesthetic organizations. In November, 2016, Dr. Schaison
joined Syneron Medical Ltd., (NASDAQ:ELOS), a leading global
aesthetic device company, and currently serves as CEO of Syneron
Candela North America and Global Executive Vice President Strategy
and Business Development. Previously, Dr. Schaison served as
President of Allergan’s U.S. aesthetic and dermatology business. In
that position, he led the Facial Aesthetic, Plastic and
MedDerm/Skin Medical business unit, an organization of over 2,000
professionals focused on the company’s Botox® and fillers
franchises.
Prior to joining Allergan, Dr. Schaison served
as President, World Wide Travel Retail & Regional President,
LATAM and MEA, at Clarins in New York. Earlier, Dr. Schaison served
as CEO for Aesthetic Factors, a manufacturer of point-of-care
systems for regenerative medicines and as Vice President of Global
Skin Care for Johnson & Johnson, with P&L responsibility
for Aveeno, Clean & Clear, Lubriderm, and Ambi, and in
executive positions at L'Oréal. Dr. Schaison sits on the Board of
the Galien Foundation and SENTÉ, Inc., a privately held specialty
aesthetics company. He earned his MBA (Marketing) from the Hautes
Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy
(Industrial) from the University of Paris.
About SientraHeadquartered in
Santa Barbara, California, Sientra is a medical aesthetics company
committed to making a difference in patients’ lives by enhancing
their body image, growing their self-esteem and restoring their
confidence. The Company was founded to provide greater choice to
board-certified plastic surgeons and patients in need of medical
aesthetics products. The Company has developed a broad portfolio of
products with technologically differentiated characteristics,
supported by independent laboratory testing and strong clinical
trial outcomes. The Company sells its breast implants and breast
tissue expanders exclusively to board-certified and
board-admissible plastic surgeons and tailors its customer service
offerings to their specific needs. The Company also offers a
range of other aesthetic and specialty products including
bioCorneum®, the professional choice in scar management.
Forward-looking statementsAny forward-looking
statements are subject to risks and uncertainties such as those
described in Sientra’s most recently filed Quarterly Report on Form
10-Q and and its Annual Report on Form 10-K for the year ended
December 31, 2015 which Sientra filed with the Securities and
Exchange Commission on March 10, 2016. Actual results may
differ materially from anticipated results.
Investor Contacts:
Patrick F. Williams
Sientra, Chief Financial Officer
(619) 675-1047
patrick.williams@sientra.com
Nick Laudico / Brian Johnston
The Ruth Group
(646) 536-7030 / (646) 536-7028
IR@Sientra.com
Grafico Azioni Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Storico
Da Giu 2023 a Giu 2024